We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ISRG Stock Worth Buying as Growth Stays Strong but Risks Rise
Read MoreHide Full Article
Key Takeaways
ISRG revenues rose 18.5% to $2.89 billion as worldwide da Vinci and Ion procedures increased 16%.
Intuitive Surgical held $8.63 billion in liquidity and generated $1.8 billion in first-half free cash flow.
Tariffs, weaker bariatric demand, China pressure and trade-in-heavy placements keep execution risks elevated.
Intuitive Surgical (ISRG - Free Report) still offers investors a high-quality growth profile, but the case is not just about procedure gains.
The buy-or-wait debate depends on whether procedure growth, recurring revenues and financial flexibility can offset tariff pressure, mix changes and uneven hospital capital spending.
ISRG Still Has a Durable Growth Engine
Intuitive Surgical’s growth engine is driven by strong performance across all its segments. Revenues rose 18.5% year over year to $2.89 billion, helped by higher procedure volumes, system leasing revenues, installed-base expansion and rising service revenues.
Worldwide procedures across da Vinci and Ion increased 16%. Da Vinci procedures grew roughly 15%, while Ion procedures advanced 36%, showing growth from the core surgical platform and newer diagnostic applications.
The installed base also supports a compounding model. Intuitive Surgical placed 468 da Vinci systems, including 246 da Vinci 5 systems, and placed 55 Ion systems.
Medtronic plc (MDT - Free Report) remains a relevant comparison as surgical robotics becomes a broader medtech battleground. Johnson & Johnson (JNJ - Free Report) also belongs in the discussion as large device companies invest in operating-room platforms.
Intuitive Surgical ended the second quarter with $8.63 billion in cash, cash equivalents and investments, up $650 million sequentially. That liquidity matters because this business requires constant investment.
The company generated $1.8 billion of free cash flow in the first half of 2026, up 71% from the prior-year period. Cash generation funded $379 million of share repurchases and $112 million of capital expenditures.
This financial base gives Intuitive Surgical room to keep investing through cycles. Management is prioritizing research and development growth to support platforms, instruments and digital capabilities.
The caution case starts with margins. Intuitive Surgical raised its 2026 adjusted gross margin outlook to 68-69%, but that range still includes an estimated tariff impact equal to 1% of revenues.
Second-quarter adjusted gross margin was 70%, helped by a $36 million pretax refund of previously paid tariffs. Excluding that benefit, the margin would have been 68.7%.
Procedure mix is another constraint. U.S. da Vinci procedures rose 12%, down from 14% in the first quarter, as some benign procedures were deferred.
Bariatric procedures declined at a high-single-digit rate amid greater GLP-1 use. Cholecystectomy growth and lower bariatric volumes also limited instrument and accessory revenue per procedure.
System placement trends need context. Da Vinci placements rose 18.5% year over year to 468 systems, but about half of U.S. placements were trade-ins.
Leasing gives hospitals more flexibility, representing 54% of total da Vinci placements. Still, capital purchases remain sensitive to hospital budgets, financing conditions and government tender timing.
Outside the United States, China remains a pressure point because of lower tender activity, domestic competition and policy-driven pricing. Parts of Europe also face government budget constraints.
How ISRG’s Stock Case Comes Together
ISRG’s investment case is a balance between durable quality and real execution risk. The bull case rests on recurring revenue, procedure growth, platform breadth and a cash-rich balance sheet.
The cautious case is also clear. Tariffs, regional capital cycles, weaker bariatric demand and the planned extended-use instrument program could reduce revenue per procedure before higher volumes offset the impact.
The stock’s operating profile should be paired with ISRG’s current Zacks Rank #2 (Buy) and Zacks Style Scores of B before investors form a view. The Zacks Rank focuses on earnings estimate revisions, while the Style Scores frame value, growth and momentum characteristics. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
For now, Intuitive Surgical looks more like a quality business that needs selective entry discipline than an all-clear buy. Strong growth supports the long-term story, but margin and placement risks keep the debate active.
View the Zacks #1 Rank List
Image: Shutterstock
Is ISRG Stock Worth Buying as Growth Stays Strong but Risks Rise
Key Takeaways
Intuitive Surgical (ISRG - Free Report) still offers investors a high-quality growth profile, but the case is not just about procedure gains.
The buy-or-wait debate depends on whether procedure growth, recurring revenues and financial flexibility can offset tariff pressure, mix changes and uneven hospital capital spending.
ISRG Still Has a Durable Growth Engine
Intuitive Surgical’s growth engine is driven by strong performance across all its segments. Revenues rose 18.5% year over year to $2.89 billion, helped by higher procedure volumes, system leasing revenues, installed-base expansion and rising service revenues.
Worldwide procedures across da Vinci and Ion increased 16%. Da Vinci procedures grew roughly 15%, while Ion procedures advanced 36%, showing growth from the core surgical platform and newer diagnostic applications.
The installed base also supports a compounding model. Intuitive Surgical placed 468 da Vinci systems, including 246 da Vinci 5 systems, and placed 55 Ion systems.
Medtronic plc (MDT - Free Report) remains a relevant comparison as surgical robotics becomes a broader medtech battleground. Johnson & Johnson (JNJ - Free Report) also belongs in the discussion as large device companies invest in operating-room platforms.
Intuitive Surgical’s Balance Sheet Adds Flexibility
Intuitive Surgical ended the second quarter with $8.63 billion in cash, cash equivalents and investments, up $650 million sequentially. That liquidity matters because this business requires constant investment.
The company generated $1.8 billion of free cash flow in the first half of 2026, up 71% from the prior-year period. Cash generation funded $379 million of share repurchases and $112 million of capital expenditures.
This financial base gives Intuitive Surgical room to keep investing through cycles. Management is prioritizing research and development growth to support platforms, instruments and digital capabilities.
Intuitive Surgical, Inc. Price and Consensus
Intuitive Surgical, Inc. price-consensus-chart | Intuitive Surgical, Inc. Quote
ISRG Faces Pressure on Margins and Mix
The caution case starts with margins. Intuitive Surgical raised its 2026 adjusted gross margin outlook to 68-69%, but that range still includes an estimated tariff impact equal to 1% of revenues.
Second-quarter adjusted gross margin was 70%, helped by a $36 million pretax refund of previously paid tariffs. Excluding that benefit, the margin would have been 68.7%.
Procedure mix is another constraint. U.S. da Vinci procedures rose 12%, down from 14% in the first quarter, as some benign procedures were deferred.
Bariatric procedures declined at a high-single-digit rate amid greater GLP-1 use. Cholecystectomy growth and lower bariatric volumes also limited instrument and accessory revenue per procedure.
Intuitive Surgical’s Placement Risks Deserve Attention
System placement trends need context. Da Vinci placements rose 18.5% year over year to 468 systems, but about half of U.S. placements were trade-ins.
Leasing gives hospitals more flexibility, representing 54% of total da Vinci placements. Still, capital purchases remain sensitive to hospital budgets, financing conditions and government tender timing.
Outside the United States, China remains a pressure point because of lower tender activity, domestic competition and policy-driven pricing. Parts of Europe also face government budget constraints.
How ISRG’s Stock Case Comes Together
ISRG’s investment case is a balance between durable quality and real execution risk. The bull case rests on recurring revenue, procedure growth, platform breadth and a cash-rich balance sheet.
The cautious case is also clear. Tariffs, regional capital cycles, weaker bariatric demand and the planned extended-use instrument program could reduce revenue per procedure before higher volumes offset the impact.
The stock’s operating profile should be paired with ISRG’s current Zacks Rank #2 (Buy) and Zacks Style Scores of B before investors form a view. The Zacks Rank focuses on earnings estimate revisions, while the Style Scores frame value, growth and momentum characteristics. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
For now, Intuitive Surgical looks more like a quality business that needs selective entry discipline than an all-clear buy. Strong growth supports the long-term story, but margin and placement risks keep the debate active.